孤独轨迹和痴呆风险:来自HUNT队列研究的见解
Ragnhild Holmberg Aunsmo1,2,3, Bjørn Heine Strand1,4,5, Sverre Bergh1,6
1Norwegian National Centre for Ageing and Health Vestfold Hospital Trust Tønsberg Norway.
Alzheimer's & dementia (Amsterdam, Netherlands)
|July 30, 2025
概括
随着时间的推移,持续的孤独与更高的痴呆风险有关. 然而,过渡性孤独没有显示任何关联,强调了解决慢性孤独的重要性,以潜在地延迟痴呆症发病.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 公共卫生 公共卫生
背景情况:
- 孤独是痴呆症的潜在危险因素,但现有研究提出了不一致的结果.
- 调查孤独与痴呆之间的关联的纵向研究有限.
研究的目的:
- 检查孤独的过程与痴呆症风险之间的长期关联.
- 调查持续性,短暂性或偶发性孤独是否会影响认知能力下降.
主要方法:
- 利用了来自特伦德拉格健康研究 (HUNT) 的9389名参与者的数据,跨越HUNT1,HUNT2和HUNT3.
- 使用后勤回归来分析自我报告的孤独轨迹与HUNT4 (70岁以上) 痴呆症发生之间的关系.
主要成果:
- 从中年到老年持续的孤独与痴呆的几率增加有关 (OR 1.47).
- 这种关联在调整为抑郁症时减弱了 (OR 1.28).
- 中年时期的过渡性孤独与痴呆风险没有显著的关联.
结论:
- 持续和偶发的孤独与患痴呆症的风险更高有关.
- 减少孤独感可能在缓解或延迟痴呆症发病方面发挥作用.
- 这些发现强调了解决慢性孤独在整个生命周期的公共卫生重要性.
更多相关视频
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
10.0K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
相关概念视频
Longitudinal Research
12.5K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
12.5K
Longitudinal Studies
248
Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
248
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Dementia
166
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
166
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
